Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, has signed an exclusive license agreement with the University of Pittsburgh. The agreement grants Genprex worldwide, exclusive rights to a patent application and related technology for a gene therapy targeting both type 1 and type 2 … Continue reading InvestorNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Enters Exclusive License Agreement with University of Pittsburgh